curcumin |
|
Vaxjo ID |
250 |
|
Vaccine Adjuvant Name |
curcumin |
|
Alternative Names |
Diferuloylmethane |
|
Adjuvant VO ID |
VO_0005737
|
|
Description |
Curcumin is a polyphenolic compound with anti-inflammatory, antioxidant, anti-proliferative, and immunomodulatory properties. It modulates immune cell function and enhances anti-tumor immunity |
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
Human |
|
Components |
curcumin has been considered as a potential anti-cancer molecule. Its potentialities have been recorded against the standard hallmarks of cancer such as continuous proliferation, escaping apoptosis, continuous angiogenesis, insensitivity to growth inhibitors, tissue invasion, and metastasis. |
|
Structure |
Polyphenolic molecule |
|
Molecular Weight |
368.38 g/mol |
|
Appearance |
Orange-yellow crystalline powder |
|
Preparation |
Extracted from turmeric or synthesized; used in various nanoparticle formulations: Liposomes Micelles Nanoemulsions Solid lipid nanoparticles PEG-conjugates Exosome-loaded curcumin |
|
Dosage |
Oral doses up to 3600 mg/day in human trials Exact dose as an adjuvant varies by formulation and model |
|
Function |
Finally, the conclusion has been drawn with the application of curcumin as a potential immune-adjuvant, which fearlessly could be used with immunotherapies for best outcomes. |
|
Safety |
Generally safe and non-toxic, but has low bioavailability |
| References |
Paul and Sa, 2021: Paul S, Sa G. Curcumin as an Adjuvant to Cancer Immunotherapy. Frontiers in oncology. 2021; 11; 675923. [PubMed: 34485117].
|
